Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,626 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- OncoTree
- BREAST
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,360 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02413320 | Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer(NeoSTOP) | completed | Phase 2 | 101 | Priyanka SharmaOTHER | 1 | May 10, 2021 | clinicaltrials |
| NCT02732119 | Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.(TRINITI-1) | completed | Phase 1 / Phase 2 | 104 | Novartis PharmaceuticalsINDUSTRY | 1 |
| May 5, 2021 |
| clinicaltrials |
| NCT00723125 | Carboplatin, Abraxane, Avastin as Neoadjuvant Therapy for Her2-Negative Breast Cancer | completed | Phase 2 | 60 | William Sikov MDOTHER | 1 | Apr 29, 2021 | clinicaltrials |
| NCT02041429 | Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca | completed | Phase 1 / Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01310231 | A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer | completed | Phase 2 | 40 | Ozmosis Research Inc.INDUSTRY | 1 | Apr 14, 2021 | clinicaltrials |
| NCT00365417 | Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer | completed | Phase 2 | 45 | NSABP Foundation IncNETWORK | 1 | Apr 13, 2021 | clinicaltrials |
| NCT03289819 | Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC(NIB) | completed | Phase 2 | 53 | Institut fuer FrauengesundheitOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT01009918 | Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab | completed | Phase 2 | 468 | University of South FloridaOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT01835236 | Trastuzumab & Pertuzumab Followed by T-DM1 in MBC | completed | Phase 2 | 208 | Swiss Cancer InstituteOTHER | 4 | Mar 30, 2021 | clinicaltrials |
| NCT01231659 | Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 26, 2021 | clinicaltrials |
| NCT01967823 | T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03248427 | Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.(CORALLEEN) | completed | Phase 2 | 106 | SOLTI Breast Cancer Research GroupOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT01037790 | Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer | completed | Phase 2 | 304 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 11, 2021 | clinicaltrials |
| NCT03577743 | Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 54 | Assiut UniversityOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT02687490 | Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer | completed | Phase 2 | 81 | Fudan UniversityOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT01783444 | A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.(BOLERO-6) | completed | Phase 2 | 309 | Novartis PharmaceuticalsINDUSTRY | 18 | Feb 26, 2021 | clinicaltrials |
| NCT00871858 | Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer(HORGEN) | completed | Phase 2 | 120 | Institut BergoniéOTHER | 1 | Feb 24, 2021 | clinicaltrials |
| NCT01842321 | Abiraterone Acetate in Molecular Apocrine Breast Cancer(AMA) | completed | Phase 2 | 34 | UNICANCEROTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT00470301 | Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2021 | clinicaltrials |
| NCT02685059 | Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer(GeparNuevo) | completed | Phase 2 | 174 | GBG Forschungs GmbHOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT01015131 | 18F-FLT-PET in Breast Cancer (MK-0000-139) | completed | Phase 2 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 11, 2021 | clinicaltrials |
| NCT01150513 | Docetaxel+Carboplatin vs Epirubicin+Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer | completed | Phase 2 / Phase 3 | 320 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02139358 | Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer | completed | Phase 1 / Phase 2 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04166253 | Protective Role of Vitamin D in Breast Cancer Patients Treated With Doxorubicin(VDDOXO) | completed | Phase 2 | 100 | Damanhour UniversityOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT02682693 | Denosumab as an add-on Neoadjuvant Treatment (GeparX)(GeparX) | completed | Phase 2 | 780 | GBG Forschungs GmbHOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02725489 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | completed | Phase 2 | 13 | Mary Crowley Medical Research CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02878057 | Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer(CABC006) | completed | Phase 2 | 30 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 27, 2021 | clinicaltrials |
| NCT00442260 | Doxorubicin HCL Liposome Injection (DOXIL) in Combination With Abraxane in Patients With Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 2 | West Virginia UniversityOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01289353 | Concurrent Adjuvant Carboplatin and Accelerated Radiotherapy for Triple Negative Breast Cancer | completed | Phase 1 / Phase 2 | 92 | NYU Langone HealthOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT01323530 | A Confirmation Study of Eribulin in Combination With Capecitabine | completed | Phase 1 / Phase 2 | 76 | Eisai LimitedINDUSTRY | 3 | Jan 11, 2021 | clinicaltrials |
| NCT02517593 | Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake(GENRE) | completed | Phase 1 / Phase 2 | 151 | Mayo ClinicOTHER | 2 | Dec 30, 2020 | clinicaltrials |
| NCT00958971 | Safety and Efficacy of TKI258 in FGFR1 Amplified and Non-amplified Metastatic HER2 Negative Breast Cancer | completed | Phase 2 | 43 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT02308020 | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | completed | Phase 2 | 162 | Eli Lilly and CompanyINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT00526045 | Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT00600275 | A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer | completed | Phase 1 / Phase 2 | 57 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
| NCT02447003 | Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) | completed | Phase 2 | 254 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Dec 16, 2020 | clinicaltrials |
| NCT04659551 | Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients(GIADA) | completed | Phase 2 | 43 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Dec 9, 2020 | clinicaltrials |
| NCT01271920 | Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab | completed | Phase 1 / Phase 2 | 45 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 8, 2020 | clinicaltrials |
| NCT00290745 | Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ | completed | Phase 1 / Phase 2 | 79 | University of California, San FranciscoOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT01570036 | Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax | completed | Phase 2 | 275 | George E. PeoplesINDUSTRY | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03106077 | Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer | completed | Phase 2 | 96 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT03535961 | Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer | completed | Phase 2 | 32 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT02757651 | KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response | completed | Phase 1 / Phase 2 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03819010 | Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -(DxCARTES) | completed | Phase 2 | 66 | MedSIROTHER | 2 | Nov 27, 2020 | clinicaltrials |
| NCT02280252 | Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response | completed | Phase 2 | 69 | NYU Langone HealthOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT03165149 | Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding | completed | Phase 2 / Phase 3 | 90 | Assiut UniversityOTHER | 1 | Nov 3, 2020 | clinicaltrials |
| NCT01491737 | A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer(PERTAIN) | completed | Phase 2 | 258 | Hoffmann-La RocheINDUSTRY | 8 | Oct 28, 2020 | clinicaltrials |
| NCT01629615 | A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer | completed | Phase 2 | 50 | SOLTI Breast Cancer Research GroupOTHER | 2 | Oct 28, 2020 | clinicaltrials |
Data updated 24 days agoSource updated May 10, 2021source: clinicaltrials